-
Nebulized amikacin: preventing positive cultures or VAP?
An impressive French study evaluating the effects of nebulized amikacin on the occurrence of ventilator-associated pneumonia (VAP) brought back old memories and a reminder that science moves slowly.
-
Are you safe in a hospital?
What do you see when you think back to hospital wards during the heath of the COVID-19 pandemic? Overcrowded, understaffed, chaos. What would the risk be for hospitalised patients not yet infected with SARS-CoV2 in those days?
-
Is the clinical trials enterprise broken?
Last week, I had the privilege to attend JAMA’s first ever summit in which two questions were addressed: ‘Is the clinical trials enterprise broken?’ and ‘How can it be fixed?’. The first question is rhetorical.
-
Antibiotics do more than causing resistance
A couple of days ago in a study on continuous antibiotic prophylaxis in children with severe vesicoureteral reflux was published in the NEJM. An international open-label RCT with 292 kids enrolled over a period of (!) 7 years.
-
Female surgeons do better!/?
On my way to my 85-year-old dad who suffered from paralytic ileus after laparotomic hemicolectomy, I heard the following news: “Patients from female surgeons have less long-term postoperative complications (including death)“ (see: Wallis et al., JAMA Surg.). Is that what the study really revealed?
.
acute kidney injury adaptive designs antibiotic resistance antibiotics antimicrobial resistance avian flu bad science children clinical trials community-acquired pneumonia COVID-19 data diagnostics ESCMID Global Guy Thwaites hospital infection influenza methods mpox pandemic pneumonia s. aureus self-controlled case series SNAP surgery urinary tract infection vaccine ventilator-associated pneumonia